Compare LQDT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | COLL |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2005 | 2015 |
| Metric | LQDT | COLL |
|---|---|---|
| Price | $38.73 | $35.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $40.00 | ★ $51.40 |
| AVG Volume (30 Days) | 191.1K | ★ 371.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.10 | N/A |
| EPS | ★ 0.46 | 0.40 |
| Revenue | $476,669,000.00 | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $81.65 | $88.00 |
| Revenue Growth | ★ 31.20 | 23.62 |
| 52 Week Low | $21.67 | $29.19 |
| 52 Week High | $41.28 | $50.79 |
| Indicator | LQDT | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 51.43 |
| Support Level | $36.36 | $33.91 |
| Resistance Level | $38.63 | $35.76 |
| Average True Range (ATR) | 1.15 | 1.31 |
| MACD | -0.23 | -0.13 |
| Stochastic Oscillator | 45.12 | 44.05 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Retail Supply Chain Group (RSCG), and Machinio & Software Solutions. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.